Whole-exome sequencing characterizes the landscape of somatic mutations and copy number alterations in adrenocortical carcinoma

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 3, 2015, Pages E493-E502

  Juhlin, C Christofer ^a,c   Goh, Gerald ^b   Healy, James M ^a   Fonseca, Annabelle L ^a   Scholl, Ute I ^d   Stenman, Adam ^c   Kunstman, John W ^a   Brown, Taylor C ^a   Overton, John D ^a   Mane, Shrikant M ^a   Nelson Williams, Carol ^b   Bäckdahl, Martin ^c   Suttorp, Anna Carinna ^d   Haase, Matthias ^d   Choi, Murim ^b   Schlessinger, Joseph ^a   Rimm, David L ^a   Höög, Anders ^c   Prasad, Manju L ^a   Korah, Reju ^a   Larsson, Catharina ^c   Lifton, Richard P ^b   Carling, Tobias ^a   more..

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

WNT PROTEIN;

ADOLESCENT; ADRENAL CORTEX CARCINOMA; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CDC27 GENE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COPY NUMBER VARIATION; CTNNB1 GENE; EXOME; FEMALE; GENE; GENE AMPLIFICATION; GENE DELETION; GENE ONTOLOGY; GENETIC SCREENING; GNAS GENE; HOMOZYGOSITY; HUMAN; IMMUNOHISTOCHEMISTRY; KREMEN1 GENE; MALE; MUTATIONAL ANALYSIS; NF2 GENE; PRIORITY JOURNAL; RB1 GENE; SCN7A GENE; SDK1 GENE; SEQUENCE ANALYSIS; SOMATIC HYPERMUTATION; TERT GENE; TP53 GENE; WNT SIGNALING PATHWAY; ZNRF3 GENE; ADRENAL CORTEX TUMOR; CASE CONTROL STUDY; DNA SEQUENCE; GENETICS; MIDDLE AGED; MUTATION; PROCEDURES; YOUNG ADULT;

ADOLESCENT; ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ADULT; AGED; CASE-CONTROL STUDIES; DNA COPY NUMBER VARIATIONS; EXOME; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; SEQUENCE ANALYSIS, DNA; YOUNG ADULT;

EID: 84924995394     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-3282     Document Type: Article

References (40)

1. Lebastchi AH, Kunstman JW, Carling T. Adrenocortical carcinoma: Current therapeutic state-of-the-art. J Oncol. 2012;2012:234726.
2. Else T, Kim AC, Sabolch A, et al. Adrenocortical carcinoma. Endocr Rev. 2014;35:282-326.
3. Berthon A, Martinez A, Bertherat J, Val P. Wnt/β-catenin signalling in adrenal physiology and tumour development. Mol Cell Endocrinol. 2012;351:87-95.
4. Fassnacht M, Kroiss M, Allolio B. Update in adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98:4551-4564.
5. Assié G, Letouzé E, Fassnacht M, et al. Integrated genomic characterization of adrenocortical carcinoma. Nat Genet. 2014;46:607-612.
6. Libé R, Groussin L, Tissier F, et al. Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity. Clin Cancer Res. 2007;13:844-850.
7. Lerario AM, Moraitis A, Hammer GD. Genetics and epigenetics of adrenocortical tumors. Mol Cell Endocrinol. 2014;386:67-84.
8. Tissier F, Cavard C, Groussin L, et al. Mutations of beta-catenin in adrenocortical tumors: Activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res. 2005;65:7622-7627.
9. Gaujoux S, Grabar S, Fassnacht M, et al. β-catenin activation is associated with specific clinical and pathologic characteristics and a poor outcome in adrenocortical carcinoma. Clin Cancer Res. 2011;17:328-336.
10. Heaton JH, Wood MA, Kim AC, et al. Progression to adrenocortical tumorigenesis in mice and humans through insulin-like growth factor 2 and β-catenin. Am J Pathol. 2012;181:1017-1033.
11. Liu T, Brown TC, Juhlin CC, et al. The activating TERT promoter mutation C228T is recurrent in subsets of adrenal tumors. Endocr Relat Cancer. 2014;21:427-434.
12. Stephan EA, Chung TH, Grant CS, et al. Adrenocortical carcinoma survival rates correlated to genomic copy number variants. Mol Cancer Ther. 2008;7:425-431.
13. Scholl UI, Goh G, Stölting Get al. Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism. Nat Genet. 2013;45:1050-1054.
14. Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499:214-218.
15. Loeb LA. Human cancers express mutator phenotypes: Origin, consequences and targeting. Nat Rev Cancer. 2011;11:450-457.
16. Yoshida R, Miyashita K, Inoue M, et al. Concurrent genetic alterations in DNA polymerase proofreading and mismatch repair in human colorectal cancer. Eur J Hum Genet. 2011;19:320-325.
17. Quesnel S, Verselis S, Portwine C, et al. p53 compound heterozygosity in a severely affected child with Li-Fraumeni syndrome. Oncogene. 1999;18:3970-3978.
18. Lohr JG, Stojanov P, Lawrence MS, et al. Discovery and prioritization of somatic mutations in diffuse large b-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A. 2012;109:3879-3884.
19. Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011;12:R41.
20. Zhang A, Zheng C, Lindvall C, et al. Frequent amplification of the telomerase reverse transcriptase gene in human tumors. Cancer Res. 2000;60:6230-6235.
21. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA. Highly recurrent TERT promoter mutations in human melanoma. Science. 2013;339:957-959.
22. Zhou Y, Lan J, Wang W, et al. ZNRF3 acts as a tumour suppressor by the Wnt signalling pathway in human gastric adenocarcinoma. J Mol Histol. 2013;44:555-563.
23. Cobrinik D, Ostrovnaya I, Hassimi M, Tickoo SK, Cheung IY, Cheung NK. Recurrent pre-existing and acquired DNA copy number alterations, including focal TERT gains, in neuroblastoma central nervous system metastases. Genes Chromosomes Cancer. 2013;52:1150-1166.
24. Freier K, Pungs S, Flechtenmacher C, et al. Frequent high telomerase reverse transcriptase expression in primary oral squamous cell carcinoma. J Oral Pathol Med. 2007;36:267-272.
25. Kang JU, Koo SH, Kwon KC, Park JW, Kim JM. Gain at chromosomal region 5p15.33, containing TERT, is the most frequent genetic event in early stages of non-small cell lung cancer. Cancer Genet Cytogenet. 2008;182:1-11.
26. Low KC, Tergaonkar V. Telomerase: Central regulator of all of the hallmarks of cancer. Trends Biochem Sci. 2013;38:426-434.
27. Koo BK, Spit M, Jordens I, et al. Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors. Nature. 2012;488:665-669.
28. Wang K, Zhang Y, Li X, et al. Characterization of the Kremen-binding site on Dkk1 and elucidation of the role of Kremen in Dkk-mediated Wnt antagonism. J Biol Chem. 2008;283:23371-23375.
29. Nord KH, Nilsson J, Arbajian E, et al. Recurrent chromosome 22 deletions in osteoblastoma affect inhibitors of the Wnt/beta-catenin signaling pathway. PLoS One. 2013;8:e80725-e80725.
30. Hao HX, Xie Y, Zhang Y, et al. ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner. Nature. 2012;485:195-200.
31. Waldmann J, Patsalis N, Fendrich V, et al. Clinical impact of TP53 alterations in adrenocortical carcinomas. Langenbecks Arch Surg. 2012;397:209-216.
32. Giles RH, van Es JH, Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta. 2003;1653:1-24.
33. Ragazzon B, Libé R, Gaujoux S, et al. Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers. Cancer Res. 2010;70:8276-8281.
34. Dhanasekaran N, Heasley LE, Johnson GL. G protein-coupled receptor systems involved in cell growth and oncogenesis. Endocr Rev. 1995;16:259-270.
35. Fecteau RE, Lutterbaugh J, Markowitz SD, Willis J, Guda K. GNAS mutations identify a set of right-sided, RAS mutant, villous colon cancers. PLoS One. 2014;9:e87966.
36. Wu J, Matthaei H, Maitra A, et al. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med. 2011;3:92ra66.
37. Almeida MQ, Azevedo MF, Xekouki P, et al. Activation of cyclic AMP signaling leads to different pathway alterations in lesions of the adrenal cortex caused by germline PRKAR1A defects versus those due to somatic GNAS mutations. J Clin Endocrinol Metab. 2012;97:E687-693.
38. Goh G, Scholl UI, Healy JM, et al. Recurrent activating mutation in PRKACA in cortisol-producing adrenal tumors. Nat Genet. 2014;46:613-617.
39. Di Fiore R, D'Anneo A, Tesoriere G, Vento R. RB1 in cancer: Different mechanisms of RB1 inactivation and alterations of pRb pathway in tumorigenesis. J Cell Physiol. 2013;228:1676-1687.
40. Harvey KF, Zhang X, Thomas DM. The Hippo pathway and human cancer. Nat Rev Cancer. 2013;13:246-257.